Capital One analyst Zegbeh Jallah upgrades Outlook Therapeutics (NASDAQ:OTLK) from Equal-Weight to Overweight and announces $5 price target.
Capital One Upgrades Outlook Therapeutics to Overweight, Announces $5 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.